We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

J&J Unlikely To Cut Risperdal Deals As Appeals Play Out

Law360, Philadelphia (November 29, 2016, 7:34 PM EST) -- Even after four losses — including a recent $70 million verdict — and another trial opening this week, attorneys say Johnson & Johnson is unlikely to consider settling thousands of pending...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.